Search Results
Nov 13, 2025, 17:31 ET ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight
novel combination therapy of ASC31 (a dual GLP-1R and GIPR peptide agonist) with ASC47 (a thyroid hormone receptor beta-selective small molecule targeting adipose tissue) revealed significantly greater weight and body fat reduction compared to tirzepatide or ASC31 alone in diet-induced obese
More news about: DelveInsight Business Research, LLP
Nov 13, 2025, 16:05 ET TDH Holdings, Inc. Reports First Half 2025 Financial Results
of certain publicly listed companies through various open market transactions. Our investments in marketable securities are accounted for pursuant to ASC 321 and reported at their readily determinable fair value as quoted by market exchanges in the consolidated balance sheets with change in fair value
More news about: TDH Holdings, Inc.
Nov 12, 2025, 18:30 ET Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
In head-to-head non-human primate (NHP) studies, co-formulation of ASC36 and ASC35 demonstrated a comparable pharmacokinetic profile to ASC36 and ASC35 dosed alone, supporting once-monthly SQ dosing. ASC36 monotherapy demonstrated approximately 32% greater relative body weight
More news about: Ascletis Pharma Inc.
Nov 12, 2025, 18:30 ET 歌禮宣布每月一次新一代胰澱素受體激動劑ASC36和每月一次新一代GLP-1R/GIPR雙靶點激動劑ASC35的復方制劑進入臨床開發階段
5 nmol/kg ASC36/ 8 nmol/kg ASC35,
More news about: 歌禮製藥有限公司
Nov 12, 2025, 13:39 ET Somnia Anesthesia Releases 2025 Anesthesia Labor Market Study
work-life balance, team culture, and autonomy in decision-making. Hospital vs. ASC Preferences: Hospitals remain the preferred setting for many, but inflexible schedules and outdated staffing models are driving attrition.
More news about: Somnia Anesthesia
Nov 12, 2025, 07:01 ET Diversis Capital Announces Strategic Investments and Combination of Genesis Automation Healthcare, Kermit, and Meperia to create the First End-to-End Healthcare Supply Chain and Inventory Management Platform
establish the industry's first full scope hospital and ASC supply chain and inventory management solution to combat waste, financial leakage, compliance risks, and administrative burdens on clinicians and hospital managers. Solving Hospital & ASC Multibillion-Dollar Supply Chain Crisis
More news about: Diversis
Nov 12, 2025, 07:00 ET RADCOM Delivers 16% YoY Revenue Growth and Strong Margin Expansion in Q3 2025
overall understanding of the Company's financial performance. By excluding non-cash stock-based compensation that has been expensed in accordance with ASC Topic 718, financial income (expenses) related to acquisitions, and amortization of intangible assets related to acquisitions, the Company's non-GAAP
More news about: RADCOM Ltd.
Nov 12, 2025, 07:00 ET Mastech Digital Reports Third Quarter 2025 Results
particular, because of varying available valuation methodologies, subjective assumptions, and the variety of award types that companies can use under ASC 718, we believe that providing non-GAAP financial measures that exclude these expenses allows investors to make more meaningful comparisons between our
More news about: Mastech Digital, Inc.
Nov 11, 2025, 17:31 ET Antibody-Mediated Rejection Market Set to Expand Significantly During the Forecast Period (2025-2034) Amid Advances in Diagnostics and Targeted Therapies | DelveInsight
including CSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech (Yifan Pharmaceutical), Ironwood, medac, among others.
More news about: DelveInsight Business Research, LLP
Nov 11, 2025, 08:41 ET Dialog Health Showcases Impressive, Extensive Results of Trackable Short Link Technology
across every stage of care. Developed with feedback and recommendations from a nationally recognized ambulatory surgery center (ASC) and hospital leaders, Dialog Health's short links — launched just over seven months ago — enable healthcare providers to drop, send, and monitor links
More news about: Dialog Health
Nov 10, 2025, 14:34 ET Physician Growth Partners Guides Fox Valley Orthopedics Into Next Growth Chapter With Sequel Ortho Partnership
focus on patient convenience is enabled by same-day orthopedic care through its OrthoFirst Walk-in Clinic and an FVO-owned ambulatory surgery center (ASC). In October 2025, the group
More news about: Sequel Ortho
Nov 10, 2025, 13:15 ET Physician Growth Partners Guides Fox Valley Orthopedics Into Next Growth Chapter With Sequel Ortho Partnership
focus on patient convenience is enabled by same-day orthopedic care through its OrthoFirst Walk-in Clinic and an FVO-owned ambulatory surgery center (ASC). In October 2025, the group
More news about: Physician Growth Partners
Nov 06, 2025, 16:05 ET Genpact Reports Third Quarter 2025 Results
expense. Because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use when adopting ASC 718 "Compensation-Stock Compensation," Genpact's management believes that providing non-GAAP financial measures that exclude such expenses allows investors
More news about: Genpact
Nov 06, 2025, 16:05 ET GoPro Announces Third Quarter Results
actions, including right-of-use asset impairment charges (if applicable), and the related ongoing operating lease cost of those facilities recorded under ASC 842, Leases. These expenses do not reflect expected future operating expenses and do not contribute to a meaningful evaluation of current operating
More news about: GoPro, Inc.
Nov 06, 2025, 06:30 ET Planet Fitness, Inc. Announces Third Quarter 2025 Results
specific to each of our three reportable segments, to assess the financial performance of and allocate resources to our segments in accordance with ASC 280, Segment Reporting. Corporate overhead costs not directly attributable to any individual segment are not allocated to the three segments and
More news about: Planet Fitness, Inc.
Nov 05, 2025, 16:37 ET Blue Owl Capital Corporation Announces September 30, 2025 Financial Results
Merger was accounted for as an asset acquisition in accordance with the asset acquisition method of accounting as detailed in ASC 805-50, Business Combinations—Related Issues ("ASC 805"). The consideration paid to the stockholders of OBDE was allocated to the individual assets acquired and liabilities assumed
More news about: Blue Owl Capital Corporation
Nov 05, 2025, 16:01 ET PTC ANNOUNCES FOURTH FISCAL QUARTER AND FULL FISCAL YEAR 2025 RESULTS
Revenue and, as a result, operating margin and earnings per share are impacted under ASC 606.
More news about: PTC Inc.
Nov 05, 2025, 08:01 ET PracticeCore, the first MSO Dedicated Exclusively to Neurosurgery, Brain, and Spine Care
clearance. Coding & Charge Integrity: Professional coding for clinic, hospital OR, and ASC; NCCI edits; modifier accuracy; charge capture reconciliation. Claims & Cash
More news about: PracticeCore
Nov 05, 2025, 08:00 ET Ardmore Shipping Corporation Announces Financial Results For The Three and Nine Months Ended September 30, 2025
HAMILTON, Bermuda, Nov. 5, 2025 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and nine months ended September 30, 2025.
More news about: Ardmore Shipping Corporation
Nov 05, 2025, 06:35 ET Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations
ended September 28, 2024 are primarily due to $3.4 million of tax expense on pre-tax non-GAAP adjustments, the interim tax accounting requirements in ASC 740 - Income Taxes, which include the removal of (1) $13.6 million of tax impact related to an inter-company sale of intellectual property, (2) $2.7
More news about: Perrigo Company plc
Nov 04, 2025, 19:10 ET 歌禮在2025年肥胖周（ObesityWeek®）報告ASC30口服片Ib期研究的完整分析、ASC30注射劑Ib期研究以及ASC31與ASC47聯合用藥臨床前研究
ASC47 與 ASC31 （新型 GLP-1R 及 GIPR 雙靶點激動劑多肽）的聯合療法在減重、減脂及不減肌方面均顯著優於替爾泊肽單藥和 ASC31
More news about: 歌禮製藥有限公司
Nov 04, 2025, 19:10 ET Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
reduction in weight of ASC31 in combination with ASC47 compared to ASC31 alone (134%) is statistically significantly higher than that of tirzepatide plus ASC47 compared to tirzepatide alone (87%). Conclusion: The combination of ASC47 and ASC31 significantly outperformed
More news about: Ascletis Pharma Inc.
Nov 04, 2025, 16:13 ET AES Reports Third Quarter 2025 Results
Mong Duong of $9 million, or $0.01 per share, partially offset by the derecognition of the valuation allowance on a loan receivable accounted for under ASC 310 and the elimination of estimated costs to sell at Mong Duong of $127 million, or $0.18 per share, after reclassification to held and used.
More news about: The AES Corporation
Nov 04, 2025, 16:05 ET Mercury General Corporation Announces Third Quarter Results and Declares Quarterly Dividend
Accounting Standards Codification ("ASC") 944-40-30-2 through 3 and Statement of Statutory Accounting Principles ("SSAP") No. 55 paragraph 15 require salvage and subrogation recoverables to
More news about: Mercury General Corporation
Nov 04, 2025, 16:01 ET ALLEGIANT TRAVEL COMPANY THIRD QUARTER 2025 FINANCIAL RESULTS
same rate as common stock. The basic and diluted earnings per share calculations for the periods presented reflect the two-class method mandated by ASC Topic 260, "Earnings Per Share." The two-class method adjusts both the net income and the shares used in the calculation. Application of the two-class
More news about: Allegiant Travel Company